- Home
- PHK vs CGEM Comparison
PHK vs CGEM Comparison
Compare PHK & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHK | CGEM |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | United States | United States |
| Employees | N/A | 109 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 861.0M | 904.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PHK | CGEM |
|---|---|---|
| Price | $4.66 | $14.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $30.13 |
| AVG Volume (30 Days) | 630.7K | ★ 713.9K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 12.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.41 | $5.68 |
| 52 Week High | $5.04 | $16.74 |
Technical Indicators
Market Signals| Indicator | PHK | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 46.95 | 54.60 |
| Support Level | $4.41 | $11.92 |
| Resistance Level | $4.74 | $15.66 |
| Average True Range (ATR) | 0.05 | 0.98 |
| MACD | -0.00 | 0.13 |
| Stochastic Oscillator | 44.29 | 62.78 |
Price Performance
Historical ComparisonAbout PHK Pimco High Income Fund
PIMCO High Income Fund is a closed-end management investment company. The company's primary investment objective is to seek high current income. The secondary objective of the company is to seek capital appreciation.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.